NewLimit logo
AIVC-backedSeries A
San Francisco, USA · Founded 2021

NewLimit

Reversing biological aging with epigenetics

Visit newlimit.com← Back to Index

About NewLimit

NewLimit is developing therapies to extend human healthspan by reprogramming the epigenome — the software layer on top of DNA that controls gene expression. Backed by Brian Armstrong (Coinbase CEO), they aim to let humans live longer, healthier lives.

Pitch deck breakdown

How NewLimit would pitch themselves.

○ Auto-generated
01

Target customer

Companies + developers adopting AI in their stack — from indie builders to enterprise ML teams working on reversing biological aging with epigenetics.

02

Problem they solve

NewLimit is developing therapies to extend human healthspan by reprogramming the epigenome — the software layer on top of DNA that controls gene expression. Backed by Brian Armstrong (Coinbase CEO), they aim to let huma… The category has historically been served by tools that miss the modern workflow this product is built around.

03

Key differentiator

NewLimit differentiates on reversing biological aging with epigenetics. Backed by Founders Fund + Foresite Capital, $40M raised — the company has resources + validation to compound this thesis. Founded by Brian Armstrong + team.

04

Go-to-market strategy

Series-A scaling stage — building outbound sales motion, hiring first AEs, layering on customer success. Mix of PLG (where the product allows) + direct sales for higher-ACV deals.

Founder of NewLimit? Submit your own pitch breakdown to replace this auto-generated overview.
Submit pitch →

NewLimit website preview

Screenshot of NewLimit (newlimit.com) — Reversing biological aging with epigenetics

Company facts

Category
AI
Funding stage
Series A
Total raised
$40M
Founded
2021
Team size
10-50
HQ
San Francisco
Country
USA
Website
newlimit.com

Founders of NewLimit

  • Brian Armstrong
  • Blake Byers

Investors backing NewLimit

  • Founders Fund
  • Foresite Capital

Frequently asked questions

What does NewLimit do?

NewLimit is developing therapies to extend human healthspan by reprogramming the epigenome — the software layer on top of DNA that controls gene expression. Backed by Brian Armstrong (Coinbase CEO), they aim to let humans live longer, healthier lives.

Where is NewLimit based?

NewLimit is based in San Francisco, USA.

When was NewLimit founded?

NewLimit was founded in 2021.

How much has NewLimit raised?

NewLimit has raised $40M in their Series A round.

Who founded NewLimit?

NewLimit was founded by Brian Armstrong, Blake Byers.

Who has invested in NewLimit?

NewLimit is backed by Founders Fund, Foresite Capital.

More AI startups